Science

Pipeline

 

CMV Immune Globulin

  •  
  • Phase I
  • Phase II
  • Phase III
Post Marketing

Therapeutic Area: CMV Disease

CYTOGAM is the only plasma-derived IgG approved in the U.S. and Canada for prophylaxis of CMV disease after Solid Organ Transplantation. CMV is the leading cause of organ rejection post-transplant.

 

Plasma Eye Drops

  •  
  • Phase I
  • Phase II
  • Phase III
Pre Clinical

Therapeutic Area: Ocular Diseases

Human plasma-based eye drops for potential treatment of several ocular conditions.